Navigation Links
Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
Date:1/15/2009

BASKING RIDGE, N.J., Jan. 15 /PRNewswire/ -- Regado Biosciences, Inc., announced today the appointment of Steven L. Zelenkofske, D.O., F.A.C.C. to the position of Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer, effective immediately. He will report to David J. Mazzo, Ph.D., the Company's President and Chief Executive Officer.

Dr. Mazzo stated, "Steven has led clinical programs for more than 15 development-stage and commercialized cardiovascular products during his pharmaceutical career and has extensive experience as a principal investigator on a number of important trials in cardiovascular medicine. His track record will be critical as Regado advances its lead therapeutic candidate, the REG1 Anticoagulation System, through late-stage clinical development." Regado recently completed enrollment in a Phase IIa clinical study (REVERSAL-PCI) of REG1 in patients undergoing elective percutaneous coronary intervention.

Dr. Zelenkofske's addition completes the new executive team at Regado. He joins recently appointed Senior Vice President of Regulatory Affairs and Quality Assurance, Dr. Alex Giaquinto and Ellen McDonald, the recently announced Senior Vice President of Business Operations and Chief Business Officer.

Most recently, Dr. Zelenkofske served as Vice President, Cardiovascular/Thrombosis Medical Unit - US at Sanofi-Aventis Pharmaceuticals and, prior to this, as Vice President of Clinical Sciences and Chief Patient Safety Officer for Boston Scientific Corporation's Cardiac Rhythm Management (CRM) Group. At both companies, Dr. Zelenkofske led the development and implementation of cardiovascular pre- and post-market clinical strategy. Prior to this, he was a senior director with Novartis Pharmaceuticals, where he held positions of increasing responsibility within its cardiovascular division, attaining the position of Senior Medical Director, US Clinical Development, Hypertension and CV Section Head. Dr. Zelenkofske also served as Director of CV Research and Clinical Director of Electrophysiology Laboratory at the Heart Care Group, where he was a physician investigator for a number of pivotal cardiovascular clinical trials, including SCD HeFT, COMPANION, MADIT, AVID and MUSTT.

Dr. Zelenkofske is the author or co-author of numerous articles published in professional journals, including the New England Journal of Medicine, Circulation, American Heart Journal and the European Heart Journal. He is a practicing electrophysiologist at Lehigh Valley Hospital in Allentown, Pennsylvania, and serves as an associate professor of medicine at the College of Medicine of the Pennsylvania State University/Hershey Medical Center and for the Philadelphia College of Osteopathic Medicine. Dr. Zelenkofske earned Bachelor of Science and Master's degrees in biochemistry and immunopharmacology at Emory University. He received a medical degree from the Philadelphia College of Osteopathic Medicine and holds certifications in clinical cardiac electrophysiology, cardiology and internal medicine.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic field with the creation and development of two-component drug systems, comprising an aptamer therapeutic that can be controlled directly by its specific and matched reversal agent. Regado's technology is designed to give physicians the ability to directly control and titrate each system's therapeutic effect. Enhanced control and flexibility allow physicians to meet the individual needs of patients independent of the setting. Regado is focusing its discovery and development efforts on acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control.

Current investors in Regado include Domain (Princeton, NJ), Quaker BioVentures (Philadelphia, PA), Aurora Funds (Durham, NC) and Caxton Advantage Life Sciences Fund (New York, NY), as well as individual investors, including Robert Kierlin.


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
2. Stevens to host Nanoscience/Nanotechnology & Corrosion symposium, Nov. 13
3. The USC Stevens Institute for Innovation Opens Shop on US Health Sciences Campus
4. Stevens researchers provide new information about mass spectrometry
5. The USC Stevens Institute for Innovation Opens Shop on USC Health Sciences Campus
6. Dr. Dinesh Verma to be honored with Presidents Leadership Award at Edwin A. Stevens Society Gala
7. Thoratec Announces Appointment of Steven H. Collis to Board of Directors
8. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
9. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
10. Ash Stevens Inc. Named One of Michigan 50 Companies to Watch
11. Cambrex Appoints Steven M. Klosk as President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... The ... 10 categories with over 30 nominees and well as the first-year award for ... award and the event was hosted by CompanyWeek and Manufacturers Edge, among other ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... nourishing a range of emerging bio and technology start-ups, is hosting “Celebration Friday” ... This double event will start with libations and networking at 3:30 p.m. at ...
(Date:4/20/2017)... ... , ... USDM Life Sciences , the leading risk management, technological innovation ... to announce Holger Braemer as Vice President of its Europe division and ... , Braemer is an integral part of USDM’s expansion of services and solutions ...
(Date:4/20/2017)... San Diego, CA (PRWEB) , ... April 20, 2017 , ... ... and management of clinical trials worldwide, announced today that they were named one of ... magazine , which covers the latest developments in the pharmaceutical industry. , “We take ...
Breaking Biology Technology:
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
Breaking Biology News(10 mins):